4000 related articles for article (PubMed ID: 19542262)
1. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
2. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[TBL] [Abstract][Full Text] [Related]
3. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.
Amato MP; Portaccio E; Goretti B; Zipoli V; Battaglini M; Bartolozzi ML; Stromillo ML; Guidi L; Siracusa G; Sorbi S; Federico A; De Stefano N
Arch Neurol; 2007 Aug; 64(8):1157-61. PubMed ID: 17698706
[TBL] [Abstract][Full Text] [Related]
4. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis.
Portaccio E; Goretti B; Zipoli V; Nacmias B; Stromillo ML; Bartolozzi ML; Siracusa G; Guidi L; Federico A; Sorbi S; De Stefano N; Amato MP
Mult Scler; 2009 Dec; 15(12):1489-94. PubMed ID: 19965518
[TBL] [Abstract][Full Text] [Related]
5. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
6. Standards for sample composition and impairment classification in neuropsychological studies of multiple sclerosis.
Benedict R
Mult Scler; 2009 Jul; 15(7):777-8. PubMed ID: 19542261
[No Abstract] [Full Text] [Related]
7. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
8. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis.
Mathiesen HK; Jonsson A; Tscherning T; Hanson LG; Andresen J; Blinkenberg M; Paulson OB; Sorensen PS
Arch Neurol; 2006 Apr; 63(4):533-6. PubMed ID: 16606765
[TBL] [Abstract][Full Text] [Related]
9. Measures in the first year of therapy predict the response to interferon beta in MS.
Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
[TBL] [Abstract][Full Text] [Related]
10. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment.
Calabrese M; Rinaldi F; Mattisi I; Grossi P; Favaretto A; Atzori M; Bernardi V; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P
Neurology; 2010 Jan; 74(4):321-8. PubMed ID: 20101038
[TBL] [Abstract][Full Text] [Related]
11. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis.
Amato MP; Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; De Stefano N
Neurology; 2008 Aug; 71(9):632-8. PubMed ID: 18725589
[TBL] [Abstract][Full Text] [Related]
12. Thalamic atrophy and cognition in multiple sclerosis.
Houtchens MK; Benedict RH; Killiany R; Sharma J; Jaisani Z; Singh B; Weinstock-Guttman B; Guttmann CR; Bakshi R
Neurology; 2007 Sep; 69(12):1213-23. PubMed ID: 17875909
[TBL] [Abstract][Full Text] [Related]
13. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
14. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
16. Impact of individual cognitive profile on visuo-motor reorganization in relapsing-remitting multiple sclerosis.
Gioia MC; Cerasa A; Liguori M; Passamonti L; Condino F; Vercillo L; Valentino P; Clodomiro A; Quattrone A; Fera F
Brain Res; 2007 Sep; 1167():71-9. PubMed ID: 17689504
[TBL] [Abstract][Full Text] [Related]
17. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.
Bellmann-Strobl J; Wuerfel J; Aktas O; Dörr J; Wernecke KD; Zipp F; Paul F
Neurology; 2009 Nov; 73(20):1624-7. PubMed ID: 19917984
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
Lanzillo R; Prinster A; Scarano V; Liuzzi R; Coppola G; Florio C; Salvatore E; Schiavone V; Brunetti A; Muto M; Orefice G; Alfano B; Bonavita V; Brescia Morra V
J Neurol Sci; 2006 Jun; 245(1-2):141-5. PubMed ID: 16626758
[TBL] [Abstract][Full Text] [Related]
19. Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment.
Portaccio E; Amato MP; Bartolozzi ML; Zipoli V; Mortilla M; Guidi L; Siracusa G; Sorbi S; Federico A; De Stefano N
J Neurol Sci; 2006 Jun; 245(1-2):195-9. PubMed ID: 16631794
[TBL] [Abstract][Full Text] [Related]
20. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.
Glanz BI; Holland CM; Gauthier SA; Amunwa EL; Liptak Z; Houtchens MK; Sperling RA; Khoury SJ; Guttmann CR; Weiner HL
Mult Scler; 2007 Sep; 13(8):1004-10. PubMed ID: 17623735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
